· Event impact
Study Shows 16% of Patients Return to Humira After Biosimilar Switch
Transmission path
Product stickiness and 're-switching' behavior mitigate the impact of patent cliffs on pharmaceutical revenue.
Market mechanism
Product stickiness and 're-switching' behavior mitigate the impact of patent cliffs on pharmaceutical revenue.
Extended read
A large-scale study of 68,000 patients reveals that while biosimilar adoption is increasing, a significant portion of patients return to the original Humira product. This 're-switching' phenomenon suggests that the competitive threat from biosimilars may be less severe than initially feared by the market. This data supports AbbVie's (ABBV) recent stock performance, as it indicates a more durable revenue stream from its flagship product even after patent expiration.
Exposed assets
ABBV
Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →